ANN ARBOR, MI -- (MARKET WIRE) -- May 25, 2007 -- Pipex Pharmaceuticals, Inc. (OTCBB: PPEX), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that the results of an open-label phase I/II clinical trial of COPREXA (oral tetrathiomolybdate) for the treatment of refractory Idiopathic Pulmonary Fibrosis (IPF) were presented at the American Thoracic Society (ATS) 2007 Annual Meeting in San Francisco by Kevin R. Flaherty, M.D., M.S., Associate Professor of Pulmonology at the University of Michigan. IPF is a fatal disorder with no FDA approved or effective therapy. This clinical trial was partially supported by a grant from the Coalition for Pulmonary Fibrosis, a non-profit organization.
